MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis

Detalles Bibliográficos
Autores principales: Fang, Wenfeng, Zhou, Huaqiang, Shen, Jiayi, Li, Jianwen, Zhang, Yaxiong, Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046406/
https://www.ncbi.nlm.nih.gov/pubmed/33551066
http://dx.doi.org/10.1136/esmoopen-2019-000614
_version_ 1783501949206790144
author Fang, Wenfeng
Zhou, Huaqiang
Shen, Jiayi
Li, Jianwen
Zhang, Yaxiong
Hong, Shaodong
Zhang, Li
author_facet Fang, Wenfeng
Zhou, Huaqiang
Shen, Jiayi
Li, Jianwen
Zhang, Yaxiong
Hong, Shaodong
Zhang, Li
author_sort Fang, Wenfeng
collection PubMed
description
format Online
Article
Text
id pubmed-7046406
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70464062020-03-09 MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis Fang, Wenfeng Zhou, Huaqiang Shen, Jiayi Li, Jianwen Zhang, Yaxiong Hong, Shaodong Zhang, Li ESMO Open Correspondence BMJ Publishing Group 2020-02-04 /pmc/articles/PMC7046406/ /pubmed/33551066 http://dx.doi.org/10.1136/esmoopen-2019-000614 Text en © Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Correspondence
Fang, Wenfeng
Zhou, Huaqiang
Shen, Jiayi
Li, Jianwen
Zhang, Yaxiong
Hong, Shaodong
Zhang, Li
MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
title MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
title_full MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
title_fullStr MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
title_full_unstemmed MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
title_short MDM2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
title_sort mdm2/4 amplification predicts poor response to immune checkpoint inhibitors: a pan-cancer analysis
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046406/
https://www.ncbi.nlm.nih.gov/pubmed/33551066
http://dx.doi.org/10.1136/esmoopen-2019-000614
work_keys_str_mv AT fangwenfeng mdm24amplificationpredictspoorresponsetoimmunecheckpointinhibitorsapancanceranalysis
AT zhouhuaqiang mdm24amplificationpredictspoorresponsetoimmunecheckpointinhibitorsapancanceranalysis
AT shenjiayi mdm24amplificationpredictspoorresponsetoimmunecheckpointinhibitorsapancanceranalysis
AT lijianwen mdm24amplificationpredictspoorresponsetoimmunecheckpointinhibitorsapancanceranalysis
AT zhangyaxiong mdm24amplificationpredictspoorresponsetoimmunecheckpointinhibitorsapancanceranalysis
AT hongshaodong mdm24amplificationpredictspoorresponsetoimmunecheckpointinhibitorsapancanceranalysis
AT zhangli mdm24amplificationpredictspoorresponsetoimmunecheckpointinhibitorsapancanceranalysis

Ejemplares similares